Handling of contagious and pathogenic agents like SARS-CoV-2 demands rigorous biosafety measures, usually in specialized facilities at biosafety level 3. The development of a considerably weakened SARS-CoV-2 version, known as the sCPD9 live-attenuated vaccine candidate, has demonstrated its safety in animal testing.
These results have led biosafety committees to permit the handling of sCPD9 in laboratories adhering to a slightly less strict BSL-2 standard. This adjustment streamlines processes and expedites research and vaccine manufacturing efforts.